Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking ...

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

Ongoing negotiations in Washington, D.C., could undermine or fundamentally alter the third iteration of the Healthy Indiana ...

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.